PT839040E - Utilizacao de inibidores da cgmp-fosfodiesterase para tratar a impotencia - Google Patents

Utilizacao de inibidores da cgmp-fosfodiesterase para tratar a impotencia

Info

Publication number
PT839040E
PT839040E PT96923985T PT96923985T PT839040E PT 839040 E PT839040 E PT 839040E PT 96923985 T PT96923985 T PT 96923985T PT 96923985 T PT96923985 T PT 96923985T PT 839040 E PT839040 E PT 839040E
Authority
PT
Portugal
Prior art keywords
impotence
fosfodiesterase
cgmp
inhibitors
treat
Prior art date
Application number
PT96923985T
Other languages
English (en)
Inventor
Alain Claude-Marie Daugan
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10777695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT839040(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icos Corp filed Critical Icos Corp
Publication of PT839040E publication Critical patent/PT839040E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Credit Cards Or The Like (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Networks Using Active Elements (AREA)
PT96923985T 1995-07-14 1996-07-11 Utilizacao de inibidores da cgmp-fosfodiesterase para tratar a impotencia PT839040E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9514464.8A GB9514464D0 (en) 1995-07-14 1995-07-14 Medicaments

Publications (1)

Publication Number Publication Date
PT839040E true PT839040E (pt) 2006-09-29

Family

ID=10777695

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96923985T PT839040E (pt) 1995-07-14 1996-07-11 Utilizacao de inibidores da cgmp-fosfodiesterase para tratar a impotencia

Country Status (25)

Country Link
US (2) US6140329A (pt)
EP (1) EP0839040B1 (pt)
JP (1) JP4169365B2 (pt)
CN (2) CN1311828C (pt)
AT (1) ATE327756T1 (pt)
AU (1) AU704955B2 (pt)
BR (1) BR9609758A (pt)
CA (1) CA2226784C (pt)
CY (2) CY2563B1 (pt)
CZ (1) CZ289686B6 (pt)
DE (1) DE69636193T2 (pt)
DK (1) DK0839040T3 (pt)
ES (1) ES2267111T3 (pt)
GB (1) GB9514464D0 (pt)
HK (1) HK1005363A1 (pt)
HU (1) HU228369B1 (pt)
IL (1) IL122870A (pt)
MX (2) MXPA02009987A (pt)
NO (1) NO314685B1 (pt)
PL (2) PL185737B1 (pt)
PT (1) PT839040E (pt)
RU (1) RU2181288C2 (pt)
SI (1) SI0839040T1 (pt)
SK (2) SK284141B6 (pt)
WO (1) WO1997003675A1 (pt)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
UA46166C2 (uk) 1997-11-12 2002-05-15 Баєр Акцієнгезельшафт 2-фенілзаміщені імідазотриазинони як інгібітори фосфодіестерази, спосіб їх одержання та лікарський засіб на їх основі
WO1999043674A1 (fr) * 1998-02-27 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Remedes contre les dysfonctionnements de l'erection
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
EP0967284A1 (en) * 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
EP1120120A4 (en) * 1998-10-05 2009-04-29 Eisai R&D Man Co Ltd TABLETS DISSOLVING DIRECTLY IN MOUTH
JP2000191518A (ja) * 1998-10-19 2000-07-11 Eisai Co Ltd 溶解性の改善された口腔内速崩壊性錠剤
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
IL135817A0 (en) * 1999-04-30 2001-05-20 Lilly Icos Llc Phosphodiesterase enzyme inhibitors and their use in pharmaceutical articles
EP1173167A4 (en) * 1999-04-30 2004-07-14 Lilly Icos Llc TREATMENT OF FEMALE SEXUAL STIMULATION DISORDERS
ES2435816T3 (es) * 1999-08-03 2013-12-23 Icos Corporation Formulación farmacéutica que comprende una Beta-carbolina y su uso para el tratamiento de la disfunción sexual
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9922124D0 (en) * 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6436944B1 (en) * 1999-09-30 2002-08-20 Pfizer Inc. Combination effective for the treatment of impotence
AU7547900A (en) 1999-10-11 2001-04-23 Pfizer Inc. 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo(4,3-d)pyrimidin-7-ones as phosphodiesterase inhibitors
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
AU2001268064A1 (en) 2000-06-07 2001-12-17 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
US20030153575A1 (en) * 2000-06-08 2003-08-14 Orme Mark W. Tetracyclic diketopiperazine compounds as pdev inhibitors
JP4169149B2 (ja) * 2000-06-23 2008-10-22 リリー アイコス リミテッド ライアビリティ カンパニー 化学的化合物
AU2001266575A1 (en) 2000-06-26 2002-01-08 Lilly Icos Llc Chemical compounds
JP4220775B2 (ja) * 2000-08-02 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー ホスホジエステラーゼ阻害剤としての融合複素環式誘導体
ES2381862T3 (es) * 2000-09-06 2012-06-01 Mitsubishi Tanabe Pharma Corporation Preparaciones para administración por vía oral
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60111553T2 (de) * 2000-10-02 2006-04-06 Lilly Icos Llc, Wilmington Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
DE60110124T2 (de) * 2000-11-08 2005-12-01 Lilly Icos Llc, Wilmington Kondensierte pyrazindionderivate als pde inhibitoren
CA2437754C (en) * 2001-02-15 2010-05-18 Tanabe Seiyaku Co., Ltd. Tablets quickly disintegrated in oral cavity
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
EP1392688B1 (en) * 2001-06-05 2008-06-04 Lilly Icos LLC Pyrazino[1',2':1,6]-pyrido[3,4-b] indole-1,4-dione derivatives
EP1421084B1 (en) * 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
CN1280292C (zh) 2001-11-14 2006-10-18 奥索-麦克尼尔药品公司 用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
ATE455758T1 (de) 2001-12-20 2010-02-15 Merck Serono Sa Pyrrolidin-derivatie als prostaglandin- modulatoren
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
AU2003257289A1 (en) 2002-07-26 2004-02-16 Kenneth W. Adams Pharmaceutical compositions for penis enlargement
WO2005068464A2 (en) * 2003-12-15 2005-07-28 Cadila Healthcare Limited Process for preparing tadalafil and its intermediates
CN102512681A (zh) 2004-05-11 2012-06-27 情感智能有限责任公司 药物制剂及其在治疗女性性功能障碍中的应用
US20060235005A1 (en) * 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
KR20080047375A (ko) 2005-07-29 2008-05-28 콘서트 파마슈티컬즈, 인크. 약제 화합물
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009542648A (ja) * 2006-07-07 2009-12-03 テバ ファーマシューティカル インダストリーズ リミティド タダラフィル及び少なくとも１種の担体を含んでなる固体組成物
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
PL2114147T3 (pl) * 2007-02-12 2012-10-31 Vyrix Pharmaceuticals Inc Zmniejszanie skutków ubocznych tramadolu
AU2008216356C1 (en) * 2007-02-12 2014-07-24 Aytu Bioscience, Inc. Treatment of comorbid premature ejaculation and erectile dysfunction
BRPI0810814A2 (pt) * 2007-04-25 2014-10-29 Teva Pharma Formas sólidas de dosagem incluindo tadalafil
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
SG190618A1 (en) 2008-05-02 2013-06-28 Gilead Sciences Inc The use of solid carrier particles to improve the processability of a pharmaceutical agent
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
AR073522A1 (es) * 2008-09-30 2010-11-10 Biolab Sanus Farmaceutica Ltda Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2010099323A1 (en) 2009-02-26 2010-09-02 Thar Pharmaceuticals, Inc. Crystalization of pharmaceutical compounds
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) * 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
UY33535A (es) * 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona
WO2013056183A1 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
MX357741B (es) * 2012-07-06 2018-07-23 Laboratorios Senosiain S A De C V Star Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
EP2903619B1 (en) 2012-10-05 2019-06-05 Robert I. Henkin Phosphodiesterase inhibitors for treating taste and smell disorders
JP2016539086A (ja) * 2013-10-07 2016-12-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 乳癌耐性タンパク質（ｂｃｒｐ）の阻害剤
CN106233141B (zh) 2014-02-18 2018-08-21 罗伯特·I·汉金 用于诊断和治疗味觉或嗅觉的损失和/或失真的方法和组合物
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
CN104086546B (zh) * 2014-07-14 2016-08-17 福建广生堂药业股份有限公司 他达拉非的药用酸盐及其制备方法
CA3046025A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
LT3510997T (lt) 2018-01-10 2021-01-11 Gap S.A. Minkšta želatinos kapsulė, apimanti tadalafilio suspensiją
CN112955967A (zh) * 2018-06-14 2021-06-11 阿斯利康(英国)有限公司 用cgmp特异性磷酸二酯酶5抑制剂医药组合物治疗勃起功能障碍的方法
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4656174A (en) * 1982-07-24 1987-04-07 Pfizer Inc. Quinoline therapeutic agents
IT1217190B (it) * 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
EP0357122A3 (en) * 1988-08-29 1991-10-23 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
DE69105040T2 (de) * 1990-05-31 1995-03-23 Pfizer, Inc., New York, N.Y. Arzneimittel gegen Impotenz.
GB9012469D0 (en) * 1990-06-05 1990-07-25 Glaxo Group Ltd Medicaments
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds

Also Published As

Publication number Publication date
CA2226784A1 (en) 1997-02-06
CN1311828C (zh) 2007-04-25
HK1005363A1 (en) 1999-01-08
CZ3398A3 (cs) 1998-05-13
PL185737B1 (pl) 2003-07-31
ATE327756T1 (de) 2006-06-15
MX9800414A (es) 1998-06-30
SK3998A3 (en) 1998-07-08
SI0839040T1 (sl) 2006-10-31
CN1112928C (zh) 2003-07-02
SK284494B6 (sk) 2005-05-05
US6140329A (en) 2000-10-31
JP4169365B2 (ja) 2008-10-22
CN1195290A (zh) 1998-10-07
PL185999B1 (pl) 2003-09-30
CA2226784C (en) 2003-07-08
CY2006007I2 (el) 2009-11-04
HUP9900065A3 (en) 1999-11-29
AU6419196A (en) 1997-02-18
AU704955B2 (en) 1999-05-13
BR9609758A (pt) 1999-01-26
CY2563B1 (en) 2008-07-02
US6608065B1 (en) 2003-08-19
DE69636193D1 (de) 2006-07-06
HUP9900065A2 (hu) 1999-05-28
CY2006007I1 (el) 2009-11-04
EP0839040B1 (en) 2006-05-31
NO980153D0 (no) 1998-01-13
PL324495A1 (en) 1998-05-25
DE69636193T2 (de) 2007-04-26
CN1513452A (zh) 2004-07-21
NO314685B1 (no) 2003-05-05
IL122870A (en) 2002-03-10
NO980153L (no) 1998-03-10
IL122870A0 (en) 1998-08-16
SK284141B6 (sk) 2004-10-05
JPH11509221A (ja) 1999-08-17
ES2267111T3 (es) 2007-03-01
DK0839040T3 (da) 2006-09-25
GB9514464D0 (en) 1995-09-13
MXPA02009987A (es) 2003-02-28
WO1997003675A1 (en) 1997-02-06
RU2181288C2 (ru) 2002-04-20
CZ289686B6 (cs) 2002-03-13
HU228369B1 (en) 2013-03-28
EP0839040A1 (en) 1998-05-06

Similar Documents

Publication Publication Date Title
PT839040E (pt) Utilizacao de inibidores da cgmp-fosfodiesterase para tratar a impotencia
GB9511220D0 (en) Solid dispersions
CA2263561A1 (en) Thienopyrimidines
CA2400554A1 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
MX9702307A (es) Pirrolo (2,3-d)pirimidinas y su uso.
TNSN92004A1 (fr) Derive de la 5h-pyrrolo (3,4-b) pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent
ES2172670T3 (es) Pirrolpirimidinas y procedimientos para su preparacion.
ATE195735T1 (de) Imidazo (4,5-c)pyridin-4-amine
PH30132A (en) 1-Substituted 1H-imidazo-[4,5-c]quinolin-4-amines
PT1165558E (pt) Derivados de pirimido¬6,1-a|isoquinolina-4-ona
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
MA27343A1 (fr) 1-amino triazolo [4,3-a] quinazoline-5-ones et/ou -5-thiones inhibitrices de phosphodiesterases iv.
CA2384037A1 (en) Pyrazolo[4,3-d]pyrimidines
AU588929B2 (en) Amino acid derivatives
TR200000371T2 (tr) 3-İkame edilen 3,4,5,7,- tetrahidro-pirrolo [3',4':4,5] tieno[2,3-D] pirimidin türevleri, üretimi ve 5HT-antagonistleri olarak kullanımları.
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
HK1016601A1 (en) Furan-and thiophenecarbothioamide derivatives, their preparation and their use as inhibitors of the replication of hiv-1 and hiv-1 mutants
PH22438A (en) Pyrido /1,2-a/ pyrimidine derivatives
ES2020176B3 (es) Composicion de apresto de alcohol polivinilico de actividad elevada en tejidos, poco espumosa.
AR013138A1 (es) Uso de derivados de azuleno como inhibidores de las metaloproteinas
MX9706878A (es) Pirazolo [3,4-d] pirimidin-4-onas 6-arilo y composiciones y metodos para su uso.